These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 33226150)
1. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Alesawy MS; Al-Karmalawy AA; Elkaeed EB; Alswah M; Belal A; Taghour MS; Eissa IH Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000237. PubMed ID: 33226150 [TBL] [Abstract][Full Text] [Related]
2. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors. Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors. El-Adl K; El-Helby AA; Sakr H; Elwan A Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors. Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352 [TBL] [Abstract][Full Text] [Related]
5. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574 [TBL] [Abstract][Full Text] [Related]
7. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
8. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer. Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440 [TBL] [Abstract][Full Text] [Related]
10. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955 [TBL] [Abstract][Full Text] [Related]
11. Pharmacophore-based, rationale design, and efficient synthesis of novel tetrahydrobenzo[b]thiophene candidates as potential dual Topo I/II inhibitors and DNA intercalators. Nofal HR; Al-Karmalawy AA; Elmaaty AA; Ismail MF; Ali AK; Abbass EM Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400217. PubMed ID: 38864845 [TBL] [Abstract][Full Text] [Related]
12. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors. Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490 [TBL] [Abstract][Full Text] [Related]
13. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation. Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914 [TBL] [Abstract][Full Text] [Related]
14. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity. Kassab AE; Gedawy EM Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830 [TBL] [Abstract][Full Text] [Related]
15. New [1,2,4]triazolo[4,3-c]quinazolines as intercalative Topo II inhibitors: Design, synthesis, biological evaluation, and in silico studies. Gaber AA; Sobhy M; Turky A; Eldehna WM; El-Sebaey SA; El-Metwally SA; El-Naggar AM; Ibrahim IM; Elkaeed EB; Metwaly AM; Eissa IH PLoS One; 2023; 18(1):e0274081. PubMed ID: 36716311 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison. Kunwar S; Hwang SY; Katila P; Park S; Jeon KH; Kim D; Kadayat TM; Kwon Y; Lee ES Eur J Med Chem; 2021 Dec; 226():113860. PubMed ID: 34597897 [TBL] [Abstract][Full Text] [Related]
17. 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation. Roque Marques KM; do Desterro MR; de Arruda SM; de Araújo Neto LN; do Carmo Alves de Lima M; de Almeida SMV; da Silva ECD; de Aquino TM; da Silva-Júnior EF; de Araújo-Júnior JX; de M Silva M; de A Dantas MD; Santos JCC; Figueiredo IM; Bazin MA; Marchand P; da Silva TG; Mendonça Junior FJB Curr Top Med Chem; 2019; 19(13):1075-1091. PubMed ID: 31223089 [TBL] [Abstract][Full Text] [Related]
18. Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors. Pedatella S; Cerchia C; Manfra M; Cioce A; Bolognese A; Lavecchia A Eur J Med Chem; 2020 Feb; 187():111960. PubMed ID: 31869654 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors. My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965 [TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of Arylnaphthalene Lignan Lactone Derivatives as Potent Topoisomerase Inhibitors. Chen W; Feng Z; Hu D; Meng J Med Chem; 2021; 17(8):856-865. PubMed ID: 32520691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]